Skip to main content
C

CF PharmTech — Investor Relations & Filings

Ticker · 2652 ISIN · CNE1000074R9 Manufacturing
Open in API
Filings indexed 2 across all filing types
Latest filing 2026-03-16 Regulatory Filings
Country CN China
Listing — 2652

About CF PharmTech

CF PharmTech is a commercial-stage organization specializing in the research, development, manufacturing, and commercialization of inhalation drugs and advanced drug-delivery technologies. The company focuses on therapeutic solutions for respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). Its product pipeline encompasses various inhalation formulations, such as metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulized solutions. Beyond proprietary drug development, the company provides contract development and manufacturing organization (CDMO) services, utilizing specialized expertise in inhalation technology to support global partners. CF PharmTech aims to deliver high-quality, affordable medicine through integrated formulation science and large-scale production capabilities to improve patient management of respiratory conditions.

Recent filings

Filing Released Lang Actions
Major Milestone CF PHARMTECH, INC. 2652.HK Announces IND Acceptance for PAH New Drug with a Globally Innovative Improved Mechanism, Marking Another Milestone for Its Precision Drug Delivery Platform
Regulatory Filings Classification · 1% confidence The document is a press release issued by CF PHARMTECH, INC. announcing the acceptance of an Investigational New Drug (IND) application by the NMPA for a new drug candidate (ICF001). It details the clinical significance, strategic value, and R&D progress of the company's pipeline. As it is a corporate announcement regarding operational/clinical milestones rather than a formal financial report, dividend notice, or governance filing, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-03-16 English
CF PharmTech (HKEX: 2652.HK) Announces NMPA Acceptance of IND Application for ICF004, a Potential First-in-Class Inhaled Dry Powder Candidate Targeting Unmet Needs in PF-ILD
Regulatory Filings Classification · 1% confidence The document is a press release issued by CF PharmTech announcing the NMPA's acceptance of an Investigational New Drug (IND) application for a new drug candidate, ICF004. It details the clinical rationale, preclinical findings, and strategic significance of this development. As it is a corporate announcement regarding operational/R&D progress rather than a financial report, dividend notice, or governance filing, it falls under the category of general regulatory announcements/corporate news.
2026-02-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.